Wenhu Zhan

List of Publications by Year
in descending order

19	401	758635 12	794141 19
papers	citations	h-index	g-index

20	20	20	623
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Antimalarial proteasome inhibitor reveals collateral sensitivity from intersubunit interactions and fitness cost of resistance. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E6863-E6870.	3.3	71
2	Integrating docking scores, interaction profiles and molecular descriptors to improve the accuracy of molecular docking: Toward the discovery of novel Akt1 inhibitors. European Journal of Medicinal Chemistry, 2014, 75, 11-20.	2.6	47
3	Structure of human immunoproteasome with a reversible and noncompetitive inhibitor that selectively inhibits activated lymphocytes. Nature Communications, 2017, 8, 1692.	5.8	45
4	Improvement of Asparagine Ethylenediamines as Anti-malarial Plasmodium-Selective Proteasome Inhibitors. Journal of Medicinal Chemistry, 2019, 62, 6137-6145.	2.9	28
5	Design, synthesis and biological evaluation of pyrazol-furan carboxamide analogues as novel Akt kinase inhibitors. European Journal of Medicinal Chemistry, 2016, 117, 47-58.	2.6	26
6	Discovery of 3,4,6-Trisubstituted Piperidine Derivatives as Orally Active, Low hERG Blocking Akt Inhibitors via Conformational Restriction and Structure-Based Design. Journal of Medicinal Chemistry, 2019, 62, 7264-7288.	2.9	23
7	Design, synthesis and antitumor activities of novel bis-aryl ureas derivatives as Raf kinase inhibitors. Bioorganic and Medicinal Chemistry, 2012, 20, 4323-4329.	1.4	20
8	Development of a Highly Selective Plasmodium falciparum Proteasome Inhibitor with Antiâ€malaria Activity in Humanized Mice. Angewandte Chemie - International Edition, 2021, 60, 9279-9283.	7.2	20
9	Discovery of pyrazole-thiophene derivatives as highly Potent, orally active Akt inhibitors. European Journal of Medicinal Chemistry, 2019, 180, 72-85.	2.6	18
10	Structure-based design, synthesis and biological evaluation of diphenylmethylamine derivatives as novel Akt1 inhibitors. European Journal of Medicinal Chemistry, 2014, 73, 167-176.	2.6	16
11	Selective Phenylimidazole-Based Inhibitors of the Mycobacterium tuberculosis Proteasome. Journal of Medicinal Chemistry, 2019, 62, 9246-9253.	2.9	14
12	Discovery of N-((3S,4S)-4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl-1H-pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity. Journal of Medicinal Chemistry, 2021, 64, 12163-12180.	2.9	14
13	Design, Synthesis, Biological Evaluation, and Molecular Docking of Novel Benzopyran and Phenylpyrazole Derivatives as Akt Inhibitors. Chemical Biology and Drug Design, 2015, 85, 770-779.	1.5	11
14	Structureâ€“Activity Relationships of Noncovalent Immunoproteasome Î²5i-Selective Dipeptides. Journal of Medicinal Chemistry, 2020, 63, 13103-13123.	2.9	10
15	Design, synthesis and biological evaluation of novel acrylamide analogues as inhibitors of BCRâ€“ABL kinase. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 5279-5282.	1.0	9
16	Phenotypic Screening-Based Identification of 3,4-Disubstituted Piperidine Derivatives as Macrophage M2 Polarization Modulators: An Opportunity for Treating Multiple Sclerosis. Journal of Medicinal Chemistry, 2019, 62, 3268-3285.	2.9	9
17	Macrocyclic Peptides that Selectively Inhibit the Mycobacterium tuberculosis Proteasome. Journal of Medicinal Chemistry, 2021, 64, 6262-6272.	2.9	9
18	Design, Synthesis, and Optimization of Macrocyclic Peptides as Species-Selective Antimalaria Proteasome Inhibitors. Journal of Medicinal Chemistry, 2022, 65, 9350-9375.	2.9	8

#	Article	IF	Citations
19	Development of a Highly Selective Plasmodium falciparum Proteasome Inhibitor with Antiâ€malaria Activity in Humanized Mice. Angewandte Chemie, 2021, 133, 9365-9369.	1.6	2